From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?
| Autor: | Pascal Lebray, Anna Sessa, Manon Allaire, Alberto Tiritilli, Mourad Medmoun, Pierre Iaria, Jean-François Cadranel |
|---|---|
| Přispěvatelé: | HAL-SU, Gestionnaire, University of Naples Federico II = Università degli studi di Napoli Federico II, Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Groupe Hospitalier Public du Sud de l'Oise [Creil] (GHPSO), University of Naples Federico II, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
NAFLD
non-alcoholic fatty liver disease medicine.medical_specialty Cirrhosis Heart disease ACE angiotensin-converting enzyme medicine.medical_treatment INR international normalised ratio Review 030204 cardiovascular system & hematology MELD model for end-stage liver disease Fontan procedure 03 medical and health sciences Liver disease Combined heart and liver transplant 0302 clinical medicine Model for End-Stage Liver Disease ALT alanine aminotransferase Internal medicine Internal Medicine Immunology and Allergy Medicine NFS NAFLD fibrosis score Gamma-glutamyltransferase BNP B-type natriuretic peptide FALD Fontan-associated liver disease [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology AFP α-fetoprotein ALP alkaline phosphatase Hepatology biology GGT gamma-glutamyltransferase business.industry AST aspartate amino transferase Congestive hepatopathy Fontan-associated liver disease Gastroenterology medicine.disease 3. Good health Heart failure biology.protein Cardiology 030211 gastroenterology & hepatology HCC hepatocellular carcinoma business [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology FIB-4 Fibrosis-4 index |
| Zdroj: | JHEP Reports Innovation in Hepatology JHEP Reports Innovation in Hepatology, 2021, 3 (2), pp.100249. ⟨10.1016/j.jhepr.2021.100249⟩ JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (2), pp.100249. ⟨10.1016/j.jhepr.2021.100249⟩ JHEP Reports |
| ISSN: | 2589-5559 |
| DOI: | 10.1016/j.jhepr.2021.100249⟩ |
| Popis: | International audience; Heart failure and liver disease often coexist because of systemic disorders and diseases that affect both organs as well as complex cardio-hepatic interactions. Heart failure can cause acute or chronic liver injury due to ischaemia and passive venous congestion, respectively. Congestive hepatopathy is frequently observed in patients with congenital heart disease and after the Fontan procedure, but also in older patients with chronic heart failure. As congestive hepatopathy can evolve into cirrhosis and hepatocellular carcinoma, screening for liver injury should be performed in patients with chronic cardiac diseases and after Fontan surgery. Fibrosis starts in the centro-lobular zone and will extend progressively to the portal area. Chronic liver injury can be reversible if heart function improves. However, in the case of terminal heart failure, uncontrolled by medical resources or by assistive device support, the combination of heart and liver transplants must be discussed in patients with chronic advanced liver fibrosis. In this review of the literature, we will focus on congestive hepatopathy and its complications, such as liver fibrosis and hepatocellular carcinoma, with the aim of improving the management and surveillance of patients experiencing these complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|